These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

874 related items for PubMed ID: 20015974

  • 1. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 2. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [Abstract] [Full Text] [Related]

  • 3. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 4. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 6. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 7. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V.
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [Abstract] [Full Text] [Related]

  • 8. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.
    Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G.
    Eur Heart J; 2006 Mar; 27(5):589-95. PubMed ID: 16431875
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [Abstract] [Full Text] [Related]

  • 10. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.
    Int J Cardiol; 2012 Mar 22; 155(3):378-82. PubMed ID: 21081251
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.
    J Heart Lung Transplant; 2007 Nov 22; 26(11):1079-83. PubMed ID: 18022071
    [Abstract] [Full Text] [Related]

  • 12. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep 22; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 13. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL, Seeger W, McLaughlin VV, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubin LJ.
    J Heart Lung Transplant; 2011 Dec 22; 30(12):1327-33. PubMed ID: 22055098
    [Abstract] [Full Text] [Related]

  • 14. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
    Cozzi F, Montisci R, Marotta H, Bobbo F, Durigon N, Ruscazio M, Sfriso P, Iliceto S, Todesco S.
    Eur J Clin Invest; 2006 Sep 22; 36 Suppl 3():49-53. PubMed ID: 16919011
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
    Vizza CD, Letizia C, Petramala L, Badagliacca R, Poscia R, Zepponi E, Crescenzi E, Nona A, Benedetti G, Ferrante F, Sciomer S, Fedele F.
    Regul Pept; 2008 Nov 29; 151(1-3):48-53. PubMed ID: 18796317
    [Abstract] [Full Text] [Related]

  • 17. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galiè N, Humbert M, Rainisio M, Rubin LJ, Simonneau G.
    Thorax; 2005 Dec 29; 60(12):1025-30. PubMed ID: 16055621
    [Abstract] [Full Text] [Related]

  • 18. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease.
    Ahmadi-Simab K, Hellmich B, Gross WL.
    Eur J Clin Invest; 2006 Sep 29; 36 Suppl 3():44-8. PubMed ID: 16919010
    [Abstract] [Full Text] [Related]

  • 19. Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
    Jacobs W, Boonstra A, Marcus JT, Postmus PE, Vonk-Noordegraaf A.
    J Heart Lung Transplant; 2009 Mar 29; 28(3):280-4. PubMed ID: 19285621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.